The former Johns Hopkins professor and researcher will take on the role as principal deputy commissioner in early 2024.
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
Among Bumpus’ priorities when she assumes the role will be “creating a new model” for the FDA’s Office of Regulatory Affairs, the branch that conducts inspections, monitors drug imports, and issues recalls, market withdrawals and safety alerts, Commissioner Robert Califf said in a memo to agency staff.
In moving from the chief scientist role to principal deputy commissioner, “Namandjé will continue to highlight and elevate our role as the premier science-based organization it truly is,” Califf wrote.
Bumpus came to the FDA from the Johns Hopkins University School of Medicine, where she was professor and chairperson of the Department of Pharmacology and Molecular Sciences. She conducted extensive research on drug metabolism and the effects of antivirals on humans and pathogens.
She joined the agency in August 2022, and since, in Califf’s words, “quickly elevated the research foundation, science and innovation that provides vital support for our public health mission.” Califf also credited her with being “a champion of plain language” in public health communication. READ MORE
by Jonathan Gardner
Source: biopharmadive.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
